Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

13
Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol

Transcript of Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Page 1: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Tumour Analysis-Lynch Syndrome

Dr Alan DonaldsonConsultant in Clinical Genetics

Bristol

Page 2: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Why do tumour analysis?

• To identify 1-5% of individuals whose colon cancer may be due to Lynch syndrome, for DNA analysis.

• ~15% of colon cancers are MSI high.– Generally have a better outcome.– Poorer response to 5 Fluorouracil?

Page 3: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Lynch Syndrome.Hereditary non polyposis colorectal cancer – HNPCC.

• Autosomal Dominant disorder.• Due to mutations in one of the mismatch repair

genes.– MSH2 50%– MLH1 40%– MSH6 ~7%– PMS2 <5%– (TACSD1) ~1-2%

• Accounts for 1-5% of all colon cancers.

Page 4: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Mismatch repair function.MSH6 MSH2 MSH3

TTT TTTT TTT TTTTTTTTTTTTT TTTTTTTTTTTTTT

PMS2 MLH1

HmutSHmutS

HmutLPMS1

MLH3?

Page 5: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Amsterdam Criteria• Three or more family members, one of whom is a first degree relative of

the other two, with HNPCC-related cancers*.

• Two successive affected generations.

• One or more of the HNPCC-related cancers diagnosed before age 50 years.

• Exclusion of (FAP).

* Colon, endometrial, small intestine, hepatobiliary, urinary tract.

Page 6: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Immunohistochemical (IHC) staining of the mismatch repair proteins.

MLH1 PMS2

MSH2 MSH6

Page 7: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Microsatellite instability (MSI) 1.

Page 8: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Normal tissue

Tumour tissue

Arrows indicated additional peaksand microsatellite instability.

Page 9: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Sporadic loss of MLH1.

• 10-15% of all colorectal cancers.

• Associated with DNA methylation.

• Associated with BrafV600E in colonic tumours, but not endometrial.

Page 10: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Advantages / disadvantages of MSI.

Advantages.• Better sensitivity & Specificity than IHC.• Able to detect BRAFV600E mutations.

Disadvantages.• More expensive than IHC.• Doesn’t tell you what gene is involved.

Page 11: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Who is ordering these tests?

Genetics

Dermatology

Oncology

Gynaecology

Surgery?

Pathology?

Page 12: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.
Page 13: Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.

Any Questions?